The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain
Open accessAbstract
BACKGROUND: There is a clear need to develop an objective diagnostic test for Alzheimer disease (AD). Changes in the levels of cerebrospinal fluid (CSF) tau protein and beta-amyloid 42 (Abeta42) peptide in patients with AD have been well documented, but the relationship between these biomarkers and neuropathologic changes in the brain is not established. OBJECTIVE: To study the relationship between antemortem CSF biomarker levels and Alzheimer-type neuropathologic changes in the brain. DESIGN: Cross-sectional study to correlate levels of CSF Abeta42, total tau, and phosphorylated tau protein with neuropathologic changes in the brain. SETTING: Academic research. Patients The study included 123 patients (79 with clinically diagnosed AD, 29 with other dementia, and 15 with other neurologic disease). All underwent clinical evaluation and provided antemortem lumbar CSF samples, and neuropathologic data were collected from September 11, 1990, to March 13, 2003, in the Department of Neuroscience and Neurology, University of Kuopio, Kuopio, Finland. MAIN OUTCOME MEASURES: Levels of CSF Abeta42, total tau, and phosphorylated tau protein were measured using standard commercial immunoassays. Neuropathologic evaluations included the classic silver impregnation method and immunohistochemistry for Abeta, hyperphosphorylated tau, and alpha-synuclein. RESULTS: Cerebrospinal fluid Abeta42 and tau protein levels were related to amyloid load and the presence of neurofibrillary pathologic abnormalities in the brain. Cerebrospinal fluid Abeta42 level correlated inversely with total Abeta load in the brain, and CSF tau level correlated with results of immunohistochemistry for hyperphosphorylated tau and with the presence of neocortical neurofibrillary tangles. In multivariate logistic regression analysis, the number of neuritic plaques in the brain remained a significant predictor of decreased CSF Abeta42 level and of increased CSF tau level. Based on the ratio of phosphorylated tau level to Abeta42 level, sensitivity was 91.6%, and specificity was 85.7%, with an overall accuracy of 90.2% for the presence of pathologic neuritic plaque in the brain. CONCLUSIONS: Cerebrospinal fluid Abeta42 and tau proteins are biomarkers of AD-associated pathologic changes in the brain. The combination of abnormally low CSF Abeta42 level and abnormally high CSF tau level predicted the presence of AD pathologic features with high accuracy. This combination assay may be helpful in diagnosing the presence of AD pathologic changes in the brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A characteristic biomarker profile, defined by reduced levels of Aβ42 in conjunction with elevated t-tau and p-tau, provides a robust biochemical signature for detecting AD pathology and distinguishing it from other neurodegenerative disorders72,73.”
From Artificial intelligence-driven multi-omics approaches in Alzheimer's disease: Progress, challenges, and future directions (2025) · cites this paper as [73]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Given that a CSF Aβ42 concentration lower than 500 pg/mL has been utilized as a reliable threshold for the presence of cerebral Aβ deposition in humans (7, 19, 22, 26)”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The level of CSF P-tau also does correlate with severity of PHF tau accumulation after death [81,150].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [150]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. L., & Stadlan, E. (2011) · Neurology · doi:10.1212/01.wnl.0000400650.92875.cf · Cited by 9,882
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., et al. (1998) · Neurology · doi:10.1212/wnl.51.6.1546 · Cited by 5,047
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Self-citationHansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700
Cited by
Sorted by citations
Items 301–400 of 895
Goldhardt, O., Warnhoff, I., Yakushev, I. Y., Begcevic, I., Förstl, H., Magdolen, V., Soosaipillai, A. R., Diamandis, E. P., Alexopoulos, P., & Grimmer, T. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-019-0168-6 · Cited by 43
Bridging the Gap Between Fluid Biomarkers for Alzheimer’s Disease, Model Systems, and Patients
Bjorkli, C., Sandvig, A., & Sandvig, I. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00272 · Cited by 41
Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic
Kester, M. I., Boelaarts, L., Bouwman, F. H., Vogels, R. L. C., Groot, E. R., van Elk, E. J., Blankenstein, M. A., van der Flier, W. M., & Scheltens, P. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000313534 · Cited by 42
Schelle, J., Häsler, L. M., Göpfert, J. C., Joos, T. O., Vanderstichele, H., Stoops, E., Mandelkow, E., Neumann, U., Shimshek, D. R., Staufenbiel, M., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.09.005 · Cited by 40
Geng, J., Zhang, Y., Chen, H., Shi, H., Wu, Z., Chen, J., & Luo, F. (2023) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000001933 · Cited by 41
Llorens, F., Schmitz, M., Varges, D., Kruse, N., Gotzmann, N., Gmitterová, K., Mollenhauer, B., & Zerr, I. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8259-0 · Cited by 40
Santangelo, R., Cecchetti, G., Bernasconi, M. P., Cardamone, R., Barbieri, A., Pinto, P., Passerini, G., Scomazzoni, F., Comı, G., & Magnani, G. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170186 · Cited by 42
Advantages and Pitfalls in Fluid Biomarkers for Diagnosis of Alzheimer’s Disease
Omar, S. H., & Preddy, J. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030063 · Cited by 39
Martorana, A., Esposito, Z., Lorenzo, F. D., Giacobbe, V., Sancesario, G. M., Bucchi, G., Bonnı̀, S., Bernardini, S., Sorge, R. P., Sancesario, G., et al. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0780-4 · Cited by 40
Hippocampal Subregions are Differentially Affected in the Progression to Alzheimer's Disease
Greene, S. J., Killiany, R., & Initiative, T. A. D. N. (2011) · The Anatomical Record · doi:10.1002/ar.21493 · Cited by 40
Unveiling the Complex Role of Exosomes in Alzheimer’s Disease
Sun, M., & Chen, Z. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s466821 · Cited by 39
Dynamic Blood Concentrations of Aβ1–40 and Aβ1–42 in Alzheimer’s Disease
Yang, Y.-H., Huang, L.-C., Hsieh, S.-W., & Huang, L.-J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00768 · Cited by 39
Schindler, S. E., & Fagan, A. M. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00142 · Cited by 40
CSF biomarkers in neurodegenerative and vascular dementias
Llorens, F., Schmitz, M., Ferrer, I., & Zerr, I. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.03.003 · Cited by 44
Association of Cognitive Function with Amyloid-β and Tau Proteins in the Vitreous Humor
Wright, L. M., Stein, T. D., Jun, G., Chung, J., McConnell, K. H., Fiorello, M. G., Siegel, N. H., Ness, S. D., Xia, W., Turner, K. L., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181104 · Cited by 40
Wang, Y.-R., Chuang, H.-C., Tripathi, A., Wang, Y., Ko, M., Chuang, C., & Chen, J.-C. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.0c04980 · Cited by 39
Associating Alzheimer’s disease pathology with its cerebrospinal fluid biomarkers
Bridel, C., Somers, C., Sieben, A., Rozemüller, A. J. M., Niemantsverdriet, E., Struyfs, H., Vermeiren, Y., Broeckhoven, C. V., Deyn, P. P. D., Bjerke, M., et al. (2022) · Brain · doi:10.1093/brain/awac013 · Cited by 39
Pettigrew, C., Soldan, A., Moghekar, A., Wang, M.-C., Gross, A. L., O’Brien, R., & Albert, M. (2015) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2015.09.024 · Cited by 38
Contador, J., Vargas‐Martínez, A. M., Sánchez‐Valle, R., Trapero‐Bertran, M., & Lladó, A. (2022) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-022-01439-z · Cited by 38
Zhang, W., Young, J. I., Gomez, L., Schmidt, M. A., Lukacsovich, D., Varma, A., Chen, X. S., Martin, E. R., & Wang, L. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01216-7 · Cited by 38
The Neuropsychiatric Examination of the Young-Onset Dementias
Ducharme, S., & Dickerson, B. C. (2015) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2015.01.002 · Cited by 39
CancerPDF: A repository of cancer-associated peptidome found in human biofluids
Bhalla, S., Verma, R., Kaur, H., Kumar, R., Usmani, S. S., Sharma, S., & Raghava, G. P. S. (2017) · Scientific Reports · doi:10.1038/s41598-017-01633-3 · Cited by 39
ATN status in amnestic and non-amnestic Alzheimer’s disease and frontotemporal lobar degeneration
Cousins, K. A. Q., Irwin, D. J., Wolk, D. A., Lee, E. B., Shaw, L. M. J., Trojanowski, J. Q., Re, F. D., Gibbons, G. S., Grossman, M., & Phillips, J. S. (2020) · Brain · doi:10.1093/brain/awaa165 · Cited by 39
Usefulness of Biomarkers in the Diagnosis and Prognosis of Early-Onset Cognitive Impairment
Balasa, M., Sánchez‐Valle, R., Antonell, A., Bosch, B., Olives, J., Rami, L., Castellvı́, M., Molinuevo, J. L., & Lladó, A. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132195 · Cited by 39
Afasia progresiva primaria: del síndrome a la enfermedad
Matías‐Guiu, J. A., & García-Ramos, R. (2012) · Neurología · doi:10.1016/j.nrl.2012.04.003 · Cited by 42
Pottiez, G., Yang, L., Stewart, T., Song, N., Aro, P., Galasko, D. R., Quinn, J. F., Peskind, E. R., Shi, M., & Zhang, J. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00829 · Cited by 37
Kim, D.-K., Park, J., & Choi, B. (2014) · The Journal of Toxicological Sciences · doi:10.2131/jts.39.625 · Cited by 38
CSF level of β-amyloid peptide predicts mortality in Alzheimer’s disease
Boumenir, A., Cognat, E., Sabia, S., Hourrègue, C., Lilamand, M., Dugravot, A., Bouaziz-Amar, É., Laplanche, J., Hugon, J., Singh‐Manoux, A., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0481-4 · Cited by 38
Prediction of P-tau/Aβ42 in the cerebrospinal fluid with blood microRNAs in Alzheimer’s disease
Jia, L., Zhu, M., Yang, J., Pang, Y., Wang, Q., Li, Y., Li, T., Li, F., Wang, Q., Li, Y., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02142-x · Cited by 38
Kumar, A., Sharma, M., Su, Y., Singh, S., Hsu, F., Neth, B. J., Register, T. C., Blennow, K., Zetterberg, H., Craft, S., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac262 · Cited by 37
Cerebrospinal Fluid Biomarkers for Dementia with Lewy Bodies
Mukaetova‐Ladinska, E. B., Monteith, R., & Perry, E. K. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/536538 · Cited by 37
Cheng, L., Li, W., Chen, Y., Lin, Y., Wang, B., Guo, Q., & Miao, Y. (2022) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-327864 · Cited by 36
Increased CAIDE dementia risk, cognition, CSF biomarkers, and vascular burden in healthy adults
Ecay‐Torres, M., Estanga, A., Tainta, M., Izagirre, A., García‐Sebastián, M., Villanúa, J., Clerigué, M., Iriondo, A., Urreta, I., Arrospide, A., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005824 · Cited by 38
Alm, K. H., & Bakker, A. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181210 · Cited by 38
Flotillin is a Novel Diagnostic Blood Marker of Alzheimer’s Disease
Abdullah, M., Kimura, N., Akatsu, H., Hashizume, Y., Taslima, F., Tachita, T., Iida, S., Zou, K., Matsubara, E., & Michikawa, M. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190908 · Cited by 36
Temporal trajectories of in vivo tau and amyloid-β accumulation in Alzheimer’s disease
Baek, M. S., Cho, H., Lee, H. S., Choi, J. Y., Lee, J., Ryu, Y. H., Lee, M. S., & Lyoo, C. H. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04773-3 · Cited by 37
Evaluation of dementia by acrolein, amyloid-β and creatinine
Igarashi, K., Yoshida, M., Waragai, M., & Kashiwagi, K. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.07.017 · Cited by 35
Mizoi, M., Yoshida, M., Saiki, R., Waragai, M., Uemura, K., Akatsu, H., Kashiwagi, K., & Igarashi, K. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.01.007 · Cited by 36
Popp, J., Lewczuk, P., Frommann, I., Kölsch, H., Kornhuber, J., Maier, W., & Jessen, F. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100561 · Cited by 36
Llano, D. A., Devanarayan, P., & Devanarayan, V. (2019) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000328 · Cited by 35
Blood-based biomarkers in Alzheimer’s disease: a mini-review
Padala, S. P., & NEWHOUSE, P. A. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-022-01114-1 · Cited by 39
Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses
Brunnström, H., Rawshani, N., Zetterberg, H., Blennow, K., Minthon, L., Passant, U., & Englund, E. M. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.12.005 · Cited by 35
Alzheimer's disease — Recent biomarker developments in relation to updated diagnostic criteria
Höglund, K., Fourier, A., Perret‐Liaudet, A., Zetterberg, H., Blennow, K., & Portelius, E. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.01.041 · Cited by 39
Schöll, M., Almkvist, O., Bogdanović, N., Wall, A. E., Långström, B., Viitanen, M. H., & Nordberg, A. K. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101563 · Cited by 35
Öhrfelt, A., Brinkmalm, A., Dumurgier, J., Zetterberg, H., Bouaziz-Amar, É., Hugon, J., Paquet, C., & Blennow, K. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.11.038 · Cited by 36
del Campo, M., Jongbloed, W., Twaalfhoven, H. A. M., Veerhuis, R., Blankenstein, M. A., & Teunissen, C. E. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00202 · Cited by 34
Blood Biomarkers for Alzheimer’s Disease: Much Promise, Cautious Progress
Keshavan, A., Heslegrave, A., Zetterberg, H., & Schott, J. M. (2017) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-016-0241-0 · Cited by 34
Contribution of the plasma and lymph Degradome and Peptidome to the MHC Ligandome
Santambrogio, L., & Rammensee, H. (2018) · Immunogenetics · doi:10.1007/s00251-018-1093-z · Cited by 34
Hornberger, J. C., Bae, J. P., Watson, I., Johnston, J., & Happich, M. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1277197 · Cited by 35
Reijs, B. L. R., Ramakers, I. H. G. B., Elias-Sonnenschein, L. S., Teunissen, C. E., Simmelink, M. J. A., Tsolaki, M., Wahlund, L., Waldemar, G., Hausner, L., Johannsen, P., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170564 · Cited by 34
Neurochemical biomarkers in amyotrophic lateral sclerosis
Verde, F., Silani, V., & Otto, M. (2019) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000744 · Cited by 36
Cerebrospinal fluid levels of YKL-40 in prodromal Alzheimer’s disease
Wang, L., Gao, T., Cai, T., Li, K., Zheng, P., & Liu, J. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134658 · Cited by 35
Transferrin Biosynthesized in the Brain Is a Novel Biomarker for Alzheimer’s Disease
Hoshi, K., Ito, H., Abe, E., Fuwa, T. J., Kanno, M., Murakami, Y., Abe, M., Murakami, T., Yoshihara, A., Ugawa, Y., et al. (2021) · Metabolites · doi:10.3390/metabo11090616 · Cited by 34
Using Biomarkers to Improve Detection of Alzheimer’s Disease
Biagioni, M. C., & Galvin, J. E. (2011) · Neurodegenerative Disease Management · doi:10.2217/nmt.11.11 · Cited by 35
Krance, S. H., Cogo‐Moreira, H., Rabin, J. S., Black, S. E., & Swardfager, W. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.1056-19.2019 · Cited by 36
Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: More to Come?
Zetterberg, H., & Blennow, K. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129035 · Cited by 34
CSF tau correlates with CJD disease severity and cognitive decline
Cohen, O. S., Chapman, J., Korczyn, A. D., Warman-Alaluf, N., Nitsan, Z., Appel, S. A., Kahana, E., & Rosenmann, H. (2015) · Acta Neurologica Scandinavica · doi:10.1111/ane.12441 · Cited by 33
Misfolded proteins and neurodegeneration: role of non-native cytochrome c in cell death
Santucci, R., Sinibaldi, F., Patriarca, A., Santucci, D., & Fiorucci, L. (2010) · Expert Review of Proteomics · doi:10.1586/epr.10.50 · Cited by 33
APOE Effect on Amyloid-β PET Spatial Distribution, Deposition Rate, and Cut-Points
Toledo, J. B., Habes, M., Sotiras, A., Bjerke, M., Yong Fan, A., Weiner, M. W., Shaw, L. M. J., Davatzikos, C. A., Trojanowski, J. Q., & Initiative, A. D. N. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181282 · Cited by 36
Svenningsson, A. L., Stomrud, E., Insel, P. S., Mattsson, N., Palmqvist, S., & Hansson, O. (2019) · Scientific Reports · doi:10.1038/s41598-019-47638-y · Cited by 34
Biological markers of Alzheimer?s disease
de Souza, L. C., Sarazin, M., Teixeira, A. L., Caramelli, P., dos Santos, A. M., & Dubois, B. (2014) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20130233 · Cited by 33
Gunnarsson, M. D., Lindau, M. P., Wall, A., Blennow, K., Darreh‐Shori, T., Basu, S., Nordberg, A. K., Larsson, A., Lannfelt, L., Basun, H., et al. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000281832 · Cited by 33
Primary progressive aphasia: From syndrome to disease
Matías‐Guiu, J. A., & García-Ramos, R. (2013) · Neurología (English Edition) · doi:10.1016/j.nrleng.2012.04.018 · Cited by 35
Shweiki, M. R. A., Oeckl, P., Steinacker, P., Hengerer, B., Schönfeldt‐Lecuona, C., & Otto, M. (2017) · Expert Review of Proteomics · doi:10.1080/14789450.2017.1336435 · Cited by 33
Bauer, C. M., Cabral, H., & Killiany, R. (2018) · Diagnostics · doi:10.3390/diagnostics8010014 · Cited by 32
Tao, R., Lu, Z., Ding, D., Fu, S., Hong, Z., Liang, X., Zheng, L., Xiao, Y., & Zhao, Q. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.04.003 · Cited by 32
de Frutos‐Lucas, J., Frost, N. J., Erickson, K. I., Serrano, J. M., Maestú, F., Laws, S. M., & Brown, B. M. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101173 · Cited by 34
Frye, B. M., Craft, S., Latimer, C. S., Keene, C. D., Montine, T. J., Register, T. C., Orr, M. E., Kavanagh, K., Macauley, S. L., & Shively, C. A. (2021) · American Journal of Primatology · doi:10.1002/ajp.23260 · Cited by 34
Manipulation of the diet–microbiota–brain axis in Alzheimer’s disease
Lee, D. D., Lee, V. M. ‐., & Hur, S. K. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.1042865 · Cited by 27
Sri, S., Pegasiou, C.-M., Cave, C. A., Hough, K., Wood, N. J., Gómez‐Nicola, D., Deinhardt, K., Bannerman, D. M., Perry, V. H., & Vargas‐Caballero, M. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0670-1 · Cited by 35
Álvarez-Sánchez, L., Peña-Bautista, C., Ferré-González, L., Balaguer, A., Baquero, M., Casanova-Estruch, B., & Cháfer-Pericás, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021226 · Cited by 32
Progress Update: Fluid and Imaging Biomarkers in Alzheimer’s Disease
Sutphen, C. L., Fagan, A. M., & Holtzman, D. M. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.07.031 · Cited by 31
Andersson, E., Lindblom, N., Janelidze, S., Salvadó, G., Gkanatsiou, E., Söderberg, L., Möller, C., Lannfelt, L., Ge, J., Hanrieder, J., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00810-8 · Cited by 38
How the gut microbiota impacts neurodegenerative diseases by modulating CNS immune cells
Schaible, P., Henschel, J., & Erny, D. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03371-0 · Cited by 32
Schmitz, M., Lüllmann, K., Zafar, S., Ebert, E., Wohlhage, M. C., Oikonomou, P., Schlomm, M., Mitrova, E., Beekes, M., & Zerr, I. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.11.010 · Cited by 31
Chiang, G. C.-Y., Insel, P. S., Tosun, D., Schuff, N. W., Truran‐Sacrey, D., Raptentsetsang, S. T., Thompson, P. M., Reiman, E. M., Jack, C. R., Fox, N. C., et al. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.12.010 · Cited by 31
Phosphorylation and Dephosphorylation of Tau Protein During Synthetic Torpor
Luppi, M., Hitrec, T., Cristoforo, A. D., Squarcio, F., Stanzani, A., Occhinegro, A., Chiavetta, P., Tupone, D., Zamboni, G., Amici, R., et al. (2019) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2019.00057 · Cited by 33
Structurally Distinct Polymorphs of Tau Aggregates Revealed by Nanoscale Infrared Spectroscopy
Banerjee, S., & Ghosh, A. (2021) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.1c02660 · Cited by 33
Biomarkers in Alzheimer’s Disease
Riverol, M., & López, O. L. (2011) · Frontiers in Neurology · doi:10.3389/fneur.2011.00046 · Cited by 33
The Mental Status Examination in Patients With Suspected Dementia
Grossman, M., & Irwin, D. J. (2016) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000298 · Cited by 32
Králová, K., Fousková, M., Habartová, L., Fišar, Z., Jirák, R., Raboch, J., & Setnička, V. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.04.002 · Cited by 31
Souza, L. C. D., Bertoux, M., Funkiewiez, A., Samri, D., Azuar, C., Habert, M.-O., Kas, A., Lamari, F., Sarazin, M., & Dubois, B. (2013) · Dementia & Neuropsychologia · doi:10.1590/s1980-57642013dn70100011 · Cited by 31
Traumatic brain injury and the pathways to cerebral tau accumulation
Flavin, W. P., Hosseini, H. C., Ruberti, J. W., Kavehpour, H. P., Giza, C. C., & Prins, M. L. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1239653 · Cited by 33
Liu, Y., Lü, X., Chen, M., Wei, Z., Peng, G., Yang, J., Tang, C., & Yu, P. (2023) · BioFactors · doi:10.1002/biof.2001 · Cited by 30
Fields, J. A., Swinton, M. K., Soontornniyomkij, B., Carson, A., & Achim, C. L. (2020) · AIDS · doi:10.1097/qad.0000000000002506 · Cited by 30
Kishimoto, T., Takamiya, A., Liang, K., Funaki, K., Fujita, T., Kitazawa, M., Yoshimura, M., Tazawa, Y., Horigome, T., Eguchi, Y., et al. (2020) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2020.100649 · Cited by 30
Takeda, S., Sato, N., Rakugi, H., & Morishita, R. (2010) · Molecular BioSystems · doi:10.1039/c003148h · Cited by 30
Increased cerebrospinal fluid calpain activity and microparticle levels in Alzheimer's disease
Laske, C., Stellos, K., Kempter, I., Stransky, E., Maetzler, W., Fleming, I., & Randriamboavonjy, V. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.06.003 · Cited by 30
Amyloid-β as a biomarker for Alzheimer’s disease: quantification methods in body fluids
Galozzi, S., Marcus, K., & Barkovits, K. (2015) · Expert Review of Proteomics · doi:10.1586/14789450.2015.1065183 · Cited by 30
Levels of amyloid-beta-42 and CSF pressure are directly related in patients with Alzheimer’s disease
Schirinzi, T., Lazzaro, G. D., Sancesario, G. M., Colona, V. L., Scaricamazza, E., Mercuri, N. B., Martorana, A., & Sancesario, G. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1786-8 · Cited by 31
Santangelo, R., Coppi, E., Ferrari, L. D., Bernasconi, M. P., Pinto, P., Passerini, G., Comı, G., & Magnani, G. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141122 · Cited by 29
Brunnström, H., Hansson, O., Zetterberg, H., Londos, E., & Englund, E. M. (2012) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.3881 · Cited by 29
Fluid Biomarkers in Clinical Trials of Alzheimer’s Disease Therapeutics
Ritter, A. R., & Cummings, J. L. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00186 · Cited by 29
Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement
Hampel, H. J., & Lista, S. (2013) · The journal of nutrition health & aging · doi:10.1007/s12603-013-0003-1 · Cited by 29
A Theoretical Analysis of the Synergy of Amyloid and Tau in Alzheimer’s Disease
Han, P., & Shi, J. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151206 · Cited by 29
BMP4 overexpression induces the upregulation of APP/Tau and memory deficits in Alzheimer’s disease
Zhang, X., Li, J., Ma, L., Xu, H., Cao, Y., Liang, W., Ma, J., Wang, Z. P., & Li, Y. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00435-x · Cited by 29
Ultra-High Dimensional Variable Selection for Doubly Robust Causal Inference
Tang, D., Kong, D., Pan, W., & Wang, L. (2022) · Biometrics · doi:10.1111/biom.13625 · Cited by 29
Kurihara, M., Matsubara, T., Morimoto, S., Arakawa, A., Ohse, K., Kanemaru, K., Iwata, A., Murayama, S., & Saito, Y. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01758-3 · Cited by 29
Baldeiras, I., Santana, I. J., Leitão, M. J., Ribeiro, M. H., Pascoal, R., Duro, D., Lemos, R., Santiago, B., Almeida, M. R., & Oliveira, C. R. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2015.09.022 · Cited by 30
Chiu, M., Lue, L., Sabbagh, M. N., Chen, T., Chen, H. H., & Yang, S. (2019) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000496099 · Cited by 29
Metadata
- Authors
- Tapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T.
- Affiliations
- University of Eastern Finland (FI)
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2009-03-01
- Volume
- 66
- Issue
- 3
- Pages
- 382-9
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2075193321
- Cited by
- 896
- References
- 29
- Citations by year
- 2026: 18 · 2025: 27 · 2024: 45 · 2023: 27 · 2022: 34 · 2021: 78 · 2020: 89 · 2019: 75 · 2018: 60 · 2017: 59 · 2016: 51 · 2015: 65 · 2014: 48 · 2013: 63 · 2012: 41
- FWCI
- 32.16
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Archives of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Kuopion Yliopistollinen Sairaala
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, cerebrospinal fluid biomarkers, amyloid-beta 42, tau protein, phosphorylated tau, amyloid plaques, neurofibrillary tangles, diagnostic accuracy, lumbar CSF, neurodegeneration, alpha-synuclein, postmortem neuropathology, biomarker ratios, sensitivity and specificity
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Brain, Cross-Sectional Studies, Dementia, Female, Humans, Immunoassay, Male, Nervous System Diseases, Peptide Fragments, Retrospective Studies, ROC Curve, Logistic Models, Amyloid beta-Peptides, Silver Staining, tau Proteins, Statistics, Nonparametric, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
